Medtronic (MDT)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-14
$93.80+3.12%
Close 2026-09-14 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-14
Research Workspace
Put MDT beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is growing steadily — about 10% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 20%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskHealthy across the board
MDT's growth in key franchises and new product launches must continue to justify the price. Revenue grew 13.7% year over year, and the latest quarter beat expectations. It trades at 16× P/E versus a peer median of 28×, indicating that expectations look modest compared to our view. If MDT cuts guidance on the next call, that could negatively impact the stock. Peer multiples imply a price roughly in line with where it trades. Our read remains intact.
Trailing returns as of 2026-09-14. MDT is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 29 analysts currently covering MDT (as of Sep 2026).
Based on 14 Wall Street analysts offering 12-month price targets for MDT in the last 4 months.
Continue this research
Compare MDT with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| MDT Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put MDT next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Drive growth in key franchises and new product launches
Spinoff aligns with growth in key franchises and product launches.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
Current $93.80
The last 12 months of price, then the range of analyst 12-month targets from today’s $93.80.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Drive growth in key franchises and new product launches
New product lineup drives growth in key franchises.
Threatens: Achieve and accelerate organic revenue growth
Concerns about growth amidst strategic shifts.
Advances: Drive growth in key franchises and new product launches
Highlights growth in key franchises and new product launches.
Advances: Drive growth in key franchises and new product launches
Product wave indicates strong growth potential in key franchises.
FDA test could delay IGE push impacting growth objectives.
Advances: Achieve and accelerate organic revenue growth
Earnings call confirms strong organic revenue growth.
Advances: Drive growth in key franchises and new product launches
New product launches discussed, driving franchise growth.